logo
Maternity services in Leeds NHS hospitals downgraded by healthcare regulator

Maternity services in Leeds NHS hospitals downgraded by healthcare regulator

Independent4 hours ago

Two maternity services at NHS hospitals in Leeds have seen specific areas of care downgraded by the healthcare regulator for the first time since its founding.
Services at Leeds General Infirmary and St James's University Hospital have dropped from an overall rating of good to inadequate after an investigation by the Care and Quality Commission (CQC) into reported issues with the quality of care.
Unannounced inspections of maternity and neonatal services at the two hospitals, which come under Leeds Teaching Hospitals NHS Trust, were made in December and January after whistleblowers, service users and their families raised concerns.
It is the first time the CQC has given specific ratings for the sub-department categories of effective, caring and responsive for maternity care as a standalone service.
Specific categories for 'safe and well-led' were downgraded to inadequate, while 'effective and caring' was rated as requires improvement and 'responsive' was rated as good.
The CQC also rated the two hospitals' neonatal services as inadequate, as they were rated as standalone services for the first time.
The regulator found breaches in several areas across the hospitals and their departments.
Among the issues identified in maternity wards were dirty areas that put people at risk of infection, medicines being stored unsafely and issues around a 'blame culture' that meant staff stayed quiet about concerns.
In neonatal services at both hospitals, leaders had not ensured adequate staff levels with the right qualifications and skills, while there was no designated private space for breastfeeding and equipment was not secured safely, the report said.
Ann Ford, CQC's director of operations in the North, said: 'Prior to our visit, we had received a number of concerns from staff, people using the services and their families about the quality of care being delivered, including staff shortages in maternity at both hospitals.
'During the inspection, the concerns were substantiated, and this posed a significant risk to the safety of women, people using these services, and their babies as the staff shortages impacted on the timeliness of the care and support they received.'
Ms Ford said staff in the hospitals were working hard to provide good care to patients but 'leaders weren't listening to them' when they identified areas of concern, while she said the fact investigations were not always carried out after incidents had taken place was 'concerning'.
Babies were also being transferred between the two hospitals 'when it wasn't safe for them to do so', she added.
The overall rating for Leeds General Infirmary declined from good to requires improvement and St James's University Hospital remains rated as requires improvement. The overall rating for the trust remains rated as good.
The CQC has told Leeds Teaching Hospitals NHS Trust to submit a plan showing what action it is taking in response to these concerns.
Katie Warner, an expert medical negligence lawyer at Irwin Mitchell's Leeds office, said the findings would 'understandably cause significant anxiety for families'.
'Our clients have long-held concerns that previous CQC inspection ratings didn't accurately reflect the care on the ground families received, and things were worse than thought,' she said.
'Now that both services have been downgraded overall, our clients are now starting to feel listened to. However, the new ratings also raise serious questions about the standard of care being provided to families.'
Professor Phil Wood, chief executive of the trust, said: 'These reports have highlighted significant areas where we need to improve our maternity and neonatal services, and my priority is to make sure we urgently take action to deliver these improvements.
'I want to reassure every family due to have their baby with us in Leeds and any new parents that we are absolutely committed to providing safe, compassionate care.
'We deliver more than 8,500 babies each year and the vast majority of those are safe and positive experiences for our families. But we recognise that's not the experience of all families.
'The loss of any baby is a tragedy, and I am extremely sorry to the families who have lost their babies when receiving care in our hospitals.'
Professor Wood said the trust had 'fantastic teams of dedicated, compassionate staff in our maternity and neonatal services', and thanked those who had spoken 'openly and honestly' with the CQC during their inspections.
He added: 'I recognise we need to be better at listening to our staff and acting on their concerns and I'm sorry we have fallen short on this.
'I want to reassure staff that they can speak up and will be heard in a supportive way.'
The trust has already started making improvements to its services by recruiting 55 midwives since last autumn, while a further 35 newly qualified midwives are due to start later this year and more midwifery leadership roles have been appointed to support our clinical teams, the professor said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Symptom that hits '3 times in 24 hours' could signal Covid
Symptom that hits '3 times in 24 hours' could signal Covid

Daily Mirror

timean hour ago

  • Daily Mirror

Symptom that hits '3 times in 24 hours' could signal Covid

The latest figures also highlighted two of the most dominant Covid variants at the moment People should stay vigilant for signs of COVID-19 as there's been a marginal uptick in cases across the UK. Government data reveals that in the week up to June 15, there has been an increase in the number of confirmed Covid infections in England. This included people in hospital who were given PCR tests. Hospital admissions due to coronavirus also increased slightly compared to the previous week. ‌ The predominant strains circulating during that time were identified as LP. 8.1.1 and XFG, each contributing to 19.87 per cent of the reported cases. Also present was the "Nimbus" strain or NB.1.8.1, representing 3.97 per cent of infections. ‌ LP. 8.1.1 evolved from LP. 8.1 which itself is a descendant of Omicron, with the original LP.8.1 having surfaced in July 2024 and later categorised as a "variant under monitoring" by WHO in January. Symptoms Currently, it remains uncertain whether LP. 8.1.1 triggers specific symptoms distinctive from other strains. Thomas Jeffries, a senior microbiology lecturer at Western Sydney University, observed that LP.8.1 does not seem to be responsible for exceptionally severe symptoms. Writing for The Conversation, he said: "Notably, the symptoms of LP.8.1 don't appear to be any more severe than other circulating strains. And the WHO has evaluated the additional public health risk LP.8.1 poses at a global level to be low. "What's more, LP.8.1 remains a variant under monitoring, rather than a variant of interest or a variant of concern. In other words, these changes to the virus with LP.8.1 are small, and not likely to make a big difference to the trajectory of the pandemic." ‌ However, according to the NHS, one definitive symptom of Covid is a new or persistent cough, which may involve three or more "coughing episodes" in 24 hours. Other indicators on the list are: A high temperature or shivering (chills) – a high temperature means you feel hot to touch on your chest or back (you do not need to measure your temperature) A loss or change to your sense of smell or taste Shortness of breath Feeling tired or exhausted An aching body A headache A sore throat A blocked or runny nose Loss of appetite Diarrhoea Feeling sick or being sick. ‌ The NHS guidance for those with symptoms of Covid suggests self-isolation until recovery. For those who receive a positive Covid test result, the NHS advocates staying home and away from others for five days, although it's not legally required. Further analysis of recent Covid statistics reveals that the weekly mean positivity rate for PCR tests in English hospitals was up slightly at 6.6 per cent for the week leading up to June 15, compared to 6.2 per cent in the prior week. The total weekly hospital admission rate for COVID-19 saw a slight rise to 1.53 per 100,000 from the previous week's 1.44 per 100,000. However, the overall rate of COVID-19 patients in ICU or HDU remained steady at 0.04 per 100,000, mirroring the previous week's figure.

Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
Alzheimer's and Parkinson's charities identify new ways to reuse current drugs

South Wales Guardian

time2 hours ago

  • South Wales Guardian

Alzheimer's and Parkinson's charities identify new ways to reuse current drugs

Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases. This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added. It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service. The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost. Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases. After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials. Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses. Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's. Trial results for the Alzheimer's trial are expected to be published later this year. Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process. 'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.' Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs. 'Getting multiple drugs that are targeting the disease is really important to us,' she said. 'Testing different types of drugs and getting as many shots on target is important.' She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process. 'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.' Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'. She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas. 'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies. 'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.' She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS. And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment. 'They showed for the very first time that we were able to alter the course of the disease. 'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.' Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker. 'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'

£120m to reduce NHS waiting times in Wales announced
£120m to reduce NHS waiting times in Wales announced

South Wales Argus

time2 hours ago

  • South Wales Argus

£120m to reduce NHS waiting times in Wales announced

This comes as the latest NHS Wales performance data for April and May 2025 reveal the scale of the challenge ahead. The data show a slight increase in the number of people waiting more than two years for treatment compared to March. However, this figure is 86 per cent lower than its peak. Swansea Bay and Powys health boards have no pathways waiting longer than two years and no one-year waits for a first outpatient appointment. Hywel Dda and Aneurin Bevan university health boards each have fewer than 300 patient pathways waiting more than two years for treatment. Betsi Cadwaladr University Health Board, however, has the most pathways waiting more than two years for treatment in Wales. Mr Miles said: "It is disappointing to see the increase in long waits in April after all the progress health boards have made over the last few months. "However, this is an annual trend seen in April in Wales and also the other UK nations. "This is why we are making changes to how the NHS provides planned care and are investing £120m to bring down waiting times this year. "This new funding will mean more and faster appointments, tests and treatments over the next 12 months." Nearly 2,000 people started their cancer treatment in April, with just under 15,000 people informed they did not have cancer. Urgent and emergency care services remain busy, with the Welsh Ambulance Service experiencing the busiest May on record. Despite this, the median response time performance was exactly eight minutes, with more than 80 per cent of calls responded to within 15 minutes. The public is urged to call NHS 111 for advice to ensure they receive the right care from the appropriate NHS service for their needs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store